Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study.
Expert Opin Drug Deliv
; 13(6): 799-805, 2016 06.
Article
em En
| MEDLINE
| ID: mdl-26922837
ABSTRACT
OBJECTIVE:
The TRACER multicenter retrospective study aimed to collect data on treatment adherence in a real-life setting, in order to identify predictors of adherence at baseline.METHODS:
We recruited 384 relapsing-remitting (RR) multiple sclerosis patients with at least 12 months of use of RebiSmart®. This electronic device records the performed injections and assesses adherence as the percentage of 'not missing doses', through the connection to the iMed database. Subjects with at least 80% of completed doses at the 12 month of therapy were defined 'treatment adherents'.RESULTS:
After 12 months, 89.3% of patients were adherent; 93.2% of patients aged 26-40 years at baseline were adherent (vs 79% of the ≤25 and 87.5% of the ≥41 year olds; p = 0.006). Furthermore, 90.5% of patients with a baseline Expanded Disability Status Scale (EDSS) score <4 showed ≥80% adherence (vs 71.4% in those with EDSS score ≥4; p = 0.016). Fifty-four percent of the patients who were not adherent after 3 months were also not adherent after 12 months (OR 16.8; CI 95%7.1-39.8).CONCLUSIONS:
Patients aged 26-40 years and with an EDSS score <4 at baseline were the most adherent. The status of 'treatment adherent' in the first 3 months was predictive of higher adherence in the long term.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Cooperação do Paciente
/
Esclerose Múltipla Recidivante-Remitente
/
Interferon beta-1a
Idioma:
En
Ano de publicação:
2016
Tipo de documento:
Article